Drug Approval | August 07, 2025
Zydus receives NOC from Health Canada for ZDS-Varenicline Tablets 0.5 &1 mg
This is the group’s first NoC approval in Canada
This is the group’s first NoC approval in Canada
The operating profit (EBITDA) rose 20.7% to Rs. 156.4 crore
The India Branded Business delivered a 5% YoY growth, reaching Rs. 599 crore in revenue for the quarter
Cenexi reports an EBITDA breakeven for the quarter
Athena is also exploring the use of this technology for expanded carrier screening
The average baseline SALT score was 83.8, indicating about 16% scalp hair coverage
Vasograin Plus represents a major advancement in the treatment of migraine
Treatment with the selective NaV1.8 pain signal inhibitor VX-993 after bunionectomy surgery did not meet the primary endpoint
Innovative plate-based internalization reagents designed to deliver accurate, high-throughput, and scalable insights for GPCR and ADC research
The submission is supported by positive results from the Phase 3 AMPLIFY trial
Subscribe To Our Newsletter & Stay Updated
